Efficacy and Safety of Drug-Eluting Bead TACE in the Treatment of Primary or Secondary Liver Cancer

Table 3

The efficacy for the patients treated with DEB-TACE (mRECIST).

Evaluation	Primary liver cancer (N, %)	Secondary liver cancer (N, %)
CR	3 (7.32)	0
PR	13 (31.71)	6 (33.33)
SD	21 (51.22)	11 (61.11)
PD	4 (9.76)	1 (5.56)
DCR	90.24	94.44
ORR	39.02	33.33

CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; DCR: disease control rate; ORR: objective response rate.